3-cyclobutyl-1-methylpyrazole-4-carboxylic acid | 137614-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-cyclobutyl-1-methylpyrazole-4-carboxylic acid
• 英文别名: 3-cyclobutyl-1-methyl-1H-pyrazole-4-carboxylic acid
• CAS: 137614-13-2
• 化学式: C₉H₁₂N₂O₂
• 分子量: 180.206
• InChiKey: NXTZUDXEWDJFJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-cyclobutyl-1-methylpyrazole-4-carboxylic acid 、 2-[(3S)-1-{[4-amino-2-(difluoromethoxy)phenyl]methyl}piperidin-3-yl]propan-2-ol 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以41.4 %的产率得到3-cyclobutyl-N-[3-(difluoromethoxy)-4-{[(3S)-3-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}phenyl]-1-methyl-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  SUBSTITUTED (HETERO)ANILINES AND THEIR USE

  摘要：

  The present disclosure relates to substituted anilines and heteroanilines and their use as TRPV4 antagonists. In some embodiments, the disclosure provides a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof, wherein ring A, R groups, X, Y, Z, m, p, q, and s are defined herein.

  公开号：

  WO2024149728A1

文献信息

• [EN] KCNT1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2020227101A1

  公开（公告）日：2020-11-12

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因（例如KCNT1）中的功能增强突变的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因如KCNT1中的功能增强突变的方法。
• KCNT1 INHIBITORS AND METHODS OF USE
  申请人：Praxis Precision Medicines, Inc.

  公开号：US20220259193A1

  公开（公告）日：2022-08-18

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.